Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…
Novo Nordisk beyond weight loss has investors wary, scientists hopeful
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood…
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill…
Obesity pills from Novo Nordisk, Eli Lilly are coming
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy…
WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is best?
In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The…
Evoke phase 3 trials did not demonstrate
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of…
Markets could face ‘everything bubble’ as selloff rages on
Global stocks have fluctuated wildly over the past week, as concerns about AI valuations hang over equity markets.…
Eli Lilly hits $1 trillion market value, first for health care company
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March…
Stoxx 600, FTSE, DAX, CAC,
Millennium Wheel And Skyline At Sunset. London, England. Design Pics Editorial | Universal Images Group | Getty Images…
Novo Nordisk cuts cash prices for Wegovy, Ozempic
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.…
WeightWatchers to offer Novo Nordisk’s Wegovy pill after 2026 launch
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…